【瑞银：升药明康德目标价至82.5港元 评级“买入”】金十数据4月29日讯，瑞银的研究报告指，药明康德(02359.HK)今年首季业绩超预期。公司维持其今年的指引，持续业务收入预测按年增10%至15%，至415亿至430亿元人民币(下同)。同时，公司维持资本开支70亿至80亿元与自由现金流40亿至50亿元的目标。该行基于药明康德首季业绩微调其模型，将公司今年每股盈利预测由4.15元下调至4.12元，维持明年的每股盈利预测4.71元，并将2027年的每股盈利预测由5.37元微升至5.38元。该行将药明康德目标价由80.2港元升至82.5港元，维持评级“买入”。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.